# Navigating Primary Biliary Cholangitis in Singapore: Addressing the Diagnostic Gap and the Next-Generation Therapies

- Link: https://www.thailand-business-news.com/pr-news/navigating-primary-biliary-cholangitis-in-singapore-addressing-the-diagnostic-gap-and-the-next-generation-therapies
- Published: 2026-06-18T16:03:00+07:00
- Author: PR Newswire

◦ **90% Female Prevalence: **PBC is a critical women’s health issue, yet symptoms
   like crushing fatigue and relentless itching are frequently misdiagnosed as menopause
   or stress.
 ◦ **30-Year Innovation Gap: **This new class of therapy is the first major breakthrough
   in three decades for the 40% of patients who do not respond to traditional treatments.
 ◦ **Beyond the Blood Test: **While 80% of patients suffer from crushing fatigue,
   this new era of care prioritises a woman’s quality of life over just stable lab
   results.

**Medical Channel Asia’s spotlight on Primary Biliary Cholangitis (PBC) exposes 
how crushing fatigue and relentless itching drive severe isolation and misdiagnosis
in women, highlighting a 30-year innovation gap that finally sees hope with next-
generation targeted therapies.**

SINGAPORE, June 18, 2026 /PRNewswire/ — Primary Biliary Cholangitis (PBC) remains
a complex and widely misunderstood condition within Singapore’s healthcare landscape.
As a chronic autoimmune disease that causes the gradual destruction of the liver’s
bile ducts, it affects women in 90% of cases. However, because its early progression
is often asymptomatic or characterised by routine symptoms, a significant gap remains
between the onset of the disease and a definitive diagnosis.

As medical awareness grows, the outlook for Singaporean patients is entering a hopeful
new chapter. The clinical community is preparing for the arrival of a new class 
of breakthrough targeted therapies, representing the first major therapeutic innovation
for PBC in thirty years.

**The Clinical Profile: Why PBC Evades Early Detection**

In a healthy liver, bile ducts act as a plumbing system to drain toxins. In patients
with PBC, the immune system mistakenly attacks these ducts, leading to a toxic buildup
of bile acids that causes chronic inflammation. If left unmanaged, this slow progression
can result in permanent liver scarring (cirrhosis) and eventual liver failure.

Catching the disease early is the primary challenge for clinicians. The most common
early symptoms carry no visible physical markers and are frequently sidelined:

 ◦ Itching (Pruritus): An intense, internal sensation that cannot be scratched, 
   often leading to severe sleep deprivation, affecting up to 75% of people living
   with PBC
 ◦ Fatigue: An all-encompassing exhaustion that makes standard daily tasks feel 
   insurmountable, affects up to 80% of people living with PBC

A patient may present with stable liver enzyme levels yet remain unable to sleep,
concentrate at work, or engage with her family. This creates a central disconnect
in care: the long-standing assumption that satisfactory biochemistry equals a patient
who is thriving.

_"If a patient continues to suffer from life-altering symptoms like relentless itching
or extreme fatigue, their treatment cannot be considered fully effective — regardless
of what the biochemistry suggests." — Professor Gideon Hirschfield, University of
Toronto_

**Elevating the Standard of Care: Screening and Advanced Therapies**

For the past three decades, the standard treatment framework for PBC was limited,
relying primarily on ursodeoxycholic acid (UDCA). While UDCA slows the disease down
to the point of minimal progression for many, it leaves roughly 40% of patients 
with an incomplete response and at ongoing risk of advanced liver damage.

"Although there are some treatments for itch (in PBC patients), approximately 40
per cent of patients do not respond to treatment. Severe, intractable (hard-to-control)
itch is an indication for liver transplantation," says Dr. Thinesh Lee Krishnamoorthy,
Senior Consultant at the Department of Gastroenterology and Hepatology at Singapore
General Hospital (SGH) in [CNA](https://cnalifestyle.channelnewsasia.com/women/primary-biliary-cholangitis-autoimmune-liver-disease-transplant-581816).

A new generation of targeted therapies is now arriving in Singapore, designed specifically
to address the biological pathways that traditional treatments miss. These innovations
represent a paradigm shift:

 ◦ **Prioritising Quality of Life:** Unlike previous therapies focused solely on
   slowing liver scarring, these new treatments target the biological triggers of
   itching and fatigue.
 ◦ **Precise Care:** By focusing on the specific mechanisms of bile acid production,
   these therapies offer a customised lifeline for those who previously had no further
   medical options.

The next-generation targeted therapies arriving in Singapore—such as elafibranor,
which was registered locally in September 2025, and seladelpar—offer a highly anticipated
shift in care. These incoming treatments have shown response rates of about 50% 
to 60% in patients who did not adequately respond to traditional options.

Rather than simply managing secondary effects, these therapies are designed to regulate
bile acid production at the cellular level. "Both drugs have also demonstrated improvements
in itch symptom scores, which is a major step forward in treating the disease," 
notes Dr. Thinesh. This precise mechanism of action brings renewed hope to the patient
community by simultaneously slowing physical liver damage while directly relieving
the biological drivers of fatigue and itch.

**A Forward-Looking Approach to Long-Term Care**

Across the ASEAN region, approximately 9% of the population is estimated to be living
with a rare condition, though awareness and regulatory infrastructure remain in 
early development in several countries. Singapore’s leadership in this space is 
defined by its ability to provide visibility and clinical pathways for conditions
that have historically been the hardest to diagnose.

Singapore’s robust rare disease framework, supported by initiatives like the Rare
Disease Fund (RDF) and its 3-to-1 government matching grant, ensures that the healthcare
infrastructure is well-positioned to adopt new clinical pathways. By encouraging
proactive screening for at-risk demographics and introducing advanced, targeted 
therapies, Singapore is leading the way toward a more hopeful, predictable future
for those living with PBC.

**About Primary Biliary Cholangitis (PBC)**

PBC is a rare, autoimmune liver disease where the build-up of bile and toxins causes
chronic inflammation. It primarily affects women and can worsen over time if inadequately
treated, potentially leading to the need for a liver transplant.

**About Medical Channel Asia**

Medical Channel Asia was created to help consumers access medical information from
trustworthy sources and healthcare professionals. Medical Channel Asia reaches over
65 million users across social media and digital platforms, establishing itself 
as the largest healthcare media platform in the region.

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Navigating Primary Biliary Cholangitis in Singapore: Addressing the Diagnostic Gap and the Next-Generation Therapies ](http://www.prnasia.com/story/archive/4987001_AE87001_0?rand=184833)
